Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™

Published Online: Friday, June 1, 2012
This product bulletin was brought to you by Daiichi Sankyo, Inc.

This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.

To view the  Welchol® (colesevelam HCl) product information, please click here

To view the full product bulletin, please click here or the image below.



Related Articles
The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.
Combined with bolus insulin aspart (NovoLog), insulin degludec (Tresiba) improves long-term glycemic control in children and adolescents with type 1 diabetes.
Results show pharmacists and other healthcare providers can work together to successfully empower patients disproportionately affected by diabetes to achieve improved clinical outcomes.
Latest Issues
$auto_registration$